Mi-Ra Lee

Title: Mi-Ra Lee: Innovator in Anticancer Research

Introduction

Mi-Ra Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of medicine, particularly in the development of methods for screening anticancer agents. His innovative approach focuses on the use of integrin alpha 5 as a key component in identifying potential cancer treatments.

Latest Patents

Mi-Ra Lee holds a patent titled "Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5." This invention relates to a method for screening anticancer agents or SIP1/ZEB2 inhibitors by measuring the expression pattern of integrin alpha 5 in specific cell lines. The method allows for effective screening of potential treatments by comparing the expression levels in treated samples with those of a control. This advancement has the potential to greatly impact cancer research and therapy.

Career Highlights

Mi-Ra Lee is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work at this esteemed institution has allowed him to focus on groundbreaking research in the field of bioscience. His dedication to innovation has led to the development of methods that can be applied in medical settings, enhancing the search for effective cancer treatments.

Collaborations

Mi-Ra Lee has collaborated with notable colleagues, including Semi Kim and Hee Young Kang. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further advancing their research efforts.

Conclusion

Mi-Ra Lee's contributions to anticancer research through his innovative patent demonstrate his commitment to improving medical science. His work not only highlights the importance of integrin alpha 5 in cancer treatment but also showcases the potential for future advancements in the field.